English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
By Denny Jacob
Palatin Technologies shares rose 18% to $2.32 on news that it has entered a strategic partnership with UpScriptHealth.
The stock is down 9.4% on the year.
The biopharmaceutical company said direct-to-consumer telemedicine company UpScriptHealth will make Vyleesi, a treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder, in its proprietary platform under terms of the agreement.
Write to Denny Jacob at [email protected]
Read the full article here
